Ignite Creation Date:
2024-05-06 @ 3:23 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02272738
Status:
COMPLETED
Last Update Posted:
2017-11-21
First Post:
2014-10-18
Brief Title:
A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
Sponsor:
Osaka Medical Center for Cancer and Cardiovascular Diseases
Organization:
Osaka Medical Center for Cancer and Cardiovascular Diseases
Study Overview
Official Title:
A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose MTD for unresectable locally advanced pancreatic adenocarcinoma
Detailed Description:
Gemcitabine plus nab-Paclitaxel is one of the standard chemotherapy for metastatic pancreatic adenocarcinoma Gemcitabine plus nab-Paclitaxel realize the favorable anti-tumor effect and tolerable toxicity Gemcitabine plus nab-Paclitaxel is a promising regimen for concurrent chemoradiotherapy but the investigators need to know the safety in the case of the concurrent chemoradiotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMIN 000012254 | REGISTRY | UMIN | None |